US › Healthcare

Seres Therapeutics Inc (MCRB)

US · Healthcare · Biotechnology

$1.98-5.26%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

$593,000

Revenue YoY

+68.9%

Net profit

$-16.3M

Profit YoY

-298.5%

EPS estimate

$-1.34

Net margin

-2,746.4%

Key statistics

Market cap

$21.0M

Forward P/E

10.8

P/B

0.57

Book value

$4.63

EPS (TTM)

$-5.01

52-week high

$29.98

52-week low

$1.68

50-day MA

$3.45

200-day MA

$6.90

Beta

0.56

Analyst view

Analysts rate Seres Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $17.00.

Shareholding

Insiders

11.49%

Institutions

22.99%

Largest institutional holders

Fund	Stake
Flagship Ventures Management, Inc.	11.51%
Vanguard Capital Management, LLC	2.86%
Marshall Wace Asset Management Ltd	1.71%
Vontobel Holding Ltd.	1.22%
BlackRock Inc	1.11%
Geode Capital Management, LLC	0.80%
Susquehanna International Group, LLP	0.58%
Vanguard Fiduciary Trust Co	0.48%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Seres Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.